Keywords: herceptin/taxotere, improve, df, survival, leading, french, drugmaker

Herceptin/Taxotere improve DF survival

Article | 22 December 2006

Leading French drugmaker Sanofi-Aventis and the Breast Cancer International Research Group reported three-year median follow-up efficacy and safety data from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Aventis

Aventis Pharma

Sanofi-Aventis

Go to company listing

Related Drugs

Herceptin

trastuzumab

docetaxel

Taxotere

Carboplatin

Go to drug listing